 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- || AND019 / Hangzhou Andao Pharma
Trial completion date, Trial primary completion date, Metastases: A Study of AND019 in Women With ER Positive HER2 Negative Advanced or Metastatic Breast Cancer (clinicaltrials.gov) - Mar 2, 2024
P1, N=61, Recruiting, Sponsor: Kind Pharmaceuticals LLC
Trial completion date: May 2025 --> May 2026 | Trial primary completion date: May 2025 --> May 2026
- ||| AND019 / Hangzhou Andao Pharma
Enrollment open, Metastases: A Study of AND019 in Women With ER Positive HER2 Negative Advanced or Metastatic Breast Cancer (clinicaltrials.gov) - Dec 22, 2022
P1, N=61, Recruiting, Sponsor: Kind Pharmaceuticals LLC
Trial completion date: May 2025 --> May 2026 | Trial primary completion date: May 2025 --> May 2026 Not yet recruiting --> Recruiting
- || AND019 / Hangzhou Andao Pharma
Trial initiation date, Metastases: A Study of AND019 in Women With ER Positive HER2 Negative Advanced or Metastatic Breast Cancer (clinicaltrials.gov) - Jul 20, 2022
P1, N=61, Not yet recruiting, Sponsor: Kind Pharmaceuticals LLC
Not yet recruiting --> Recruiting Initiation date: Mar 2022 --> Aug 2022
- ||| AND019 / Hangzhou Andao Pharma
New P1 trial, Metastases: A Study of AND019 in Women With ER Positive HER2 Negative Advanced or Metastatic Breast Cancer (clinicaltrials.gov) - Jan 11, 2022
P1, N=61, Not yet recruiting, Sponsor: Kind Pharmaceuticals LLC